188 related articles for article (PubMed ID: 22974094)
1. Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects.
Saad ED; Buyse M
Acta Oncol; 2012 Sep; 51(7):890-6. PubMed ID: 22974094
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
3. Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping.
Sacher AG; Le LW; Leighl NB
J Clin Oncol; 2014 May; 32(14):1407-11. PubMed ID: 24590634
[TBL] [Abstract][Full Text] [Related]
4. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
Langer F; Helsberg K; Schütte WH; Leschinger MI
Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
[TBL] [Abstract][Full Text] [Related]
5. Non-inferiority study design: lessons to be learned from cardiovascular trials.
Head SJ; Kaul S; Bogers AJ; Kappetein AP
Eur Heart J; 2012 Jun; 33(11):1318-24. PubMed ID: 22564354
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
7. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer.
Freidlin B; Breathnach OS; Johnson BE
Clin Cancer Res; 2003 Mar; 9(3):917-22. PubMed ID: 12631588
[TBL] [Abstract][Full Text] [Related]
8. Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials.
Saad ED; Adamowicz K; Katz A; Jassem J
Cancer Treat Rev; 2012 Oct; 38(6):807-14. PubMed ID: 22445316
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials.
Di Maio M; Signoriello S; Morabito A; Rossi A; Maione P; Piantedosi F; Bilancia D; Cigolari S; Barbera S; Gebbia V; Daniele B; Robbiati SF; Illiano A; Ceribelli A; Carrozza F; Favaretto A; Piazza E; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Rocco G; Gallo C; Perrone F; Gridelli C
Lung Cancer; 2012 Jun; 76(3):457-64. PubMed ID: 22297086
[TBL] [Abstract][Full Text] [Related]
10. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
11. Issues on the selection of non-inferiority margin in clinical trials.
Hou Y; Wu XY; Li K
Chin Med J (Engl); 2009 Feb; 122(4):466-70. PubMed ID: 19302756
[TBL] [Abstract][Full Text] [Related]
12. On non-inferiority margin and statistical tests in active control trials.
Chow SC; Shao J
Stat Med; 2006 Apr; 25(7):1101-13. PubMed ID: 16345042
[TBL] [Abstract][Full Text] [Related]
13. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.
Breathnach OS; Freidlin B; Conley B; Green MR; Johnson DH; Gandara DR; O'Connell M; Shepherd FA; Johnson BE
J Clin Oncol; 2001 Mar; 19(6):1734-42. PubMed ID: 11251004
[TBL] [Abstract][Full Text] [Related]
14. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials.
Jennens RR; Giles GG; Fox RM
Intern Med J; 2006 Apr; 36(4):216-20. PubMed ID: 16640737
[TBL] [Abstract][Full Text] [Related]
15. [Methodological and statistical aspects of equivalence and non inferiority trials].
Elie C; De Rycke Y; Jais JP; Marion-Gallois R; Landais P
Rev Epidemiol Sante Publique; 2008 Aug; 56(4):267-77. PubMed ID: 18703296
[TBL] [Abstract][Full Text] [Related]
16. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.
Hotta K; Fujiwara Y; Matsuo K; Suzuki T; Kiura K; Tabata M; Takigawa N; Ueoka H; Tanimoto M
Cancer; 2007 Mar; 109(5):939-48. PubMed ID: 17285602
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
19. Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials.
Adamowicz K; Jassem J; Katz A; Saad ED
Cancer Treat Rev; 2012 Aug; 38(5):554-8. PubMed ID: 21807465
[TBL] [Abstract][Full Text] [Related]
20. Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials.
Gadgeel SM; Ivy P; Chen W; Mauer J; Smith D; Lorusso P
Clin Lung Cancer; 2011 Jul; 12(4):218-23. PubMed ID: 21726820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
